For first-line therapy in mild-to-moderate hypertension

Discover the classic benefits of a beta-blocker and a diuretic...now at low doses for a side-effect profile comparable to placebo[1]*



ZIAC controls mild-to-moderate hypertension in up to 80% of patients[1†]

ZIAC controls blood pressure for a full 24 hours for true once-a-day dosing[2]

ZIAC minimizes traditional beta-blocker- and HCTZ-associated metabolic effects (hypokalemia, hyperuricemia, hypercholesterolemia, hyperglycemia)[1]

*The two most common side effects — dizziness and fatigue — occurred at rates comparable to placebo.

†Clinical trial response rates were: 2.5 mg—61%; 5 mg—73%; 10 mg—80%.

ZIAC is contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS section of full Prescribing Information), second- or third-degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

Please see Brief Summary of Prescribing Information on adjacent page.

First-line therapy option

ZIAC™

(bisoprolol fumarate-hydrochlorothiazide)

2.5, 5, & 10 mg Tablets with 6.25 mg HCTZ

First-line therapy option

ZIAC™

(bisoprolol fumarate-hydrochlorothiazide)

2.5, 5, & 10 mg Tablets with 6.25 mg HCTZ

References:

1. DeQuattro V, Weir MR. Bisoprolol fumarate/hydrochlorothiazide 6.25 mg: a new, low-dose option for first-line antihypertensive therapy. *Adv Ther.* 1993;10:197-206.
2. Lewin AJ, Lueg MC, Targum S, *et al.* A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. *Clin Cardiol.* 1993;16:732-736.

Brief Summary

ZIAC™ (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets

FOR FULL PRESCRIBING INFORMATION, PLEASE CONSULT PACKAGE INSERT.

DESCRIPTION

ZIAC (bisoprolol fumarate and hydrochlorothiazide) is indicated for the treatment of hypertension. It combines two antihypertensive agents in a once-daily dosage: a synthetic beta$_1$-selective (cardioselective) adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide).

CLINICAL PHARMACOLOGY

At doses ≥ 20 mg bisoprolol fumarate inhibits beta$_2$-adrenoreceptors located in bronchial and vascular musculature. To retain relative selectivity, it is important to use the lowest effective dose.

CONTRAINDICATIONS

Cardiogenic shock, overt cardiac failure (see **WARNINGS**), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

WARNINGS

Cardiac Failure: Beta-blocking agents should be avoided in patients with overt congestive failure.
Patients Without a History of Cardiac Failure: Continued depression of the myocardium with beta-blockers can precipitate cardiac failure. At the first signs or symptoms of heart failure, discontinuation of ZIAC should be considered.
Abrupt Cessation of Therapy: Abrupt cessation of beta-blockers should be avoided. Even in patients without overt coronary artery disease, it may be advisable to taper therapy with ZIAC over approximately 1 week with the patient under careful observation. If withdrawal symptoms occur, beta-blocking agent therapy should be reinstituted, at least temporarily.
Peripheral Vascular Disease: Beta-blockers should be used with caution in patients with peripheral vascular disease.
Bronchospastic Disease: PATIENTS WITH BRONCHOSPASTIC PULMONARY DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS.
Anesthesia and Major Surgery: If used perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used.
Diabetes and Hypoglycemia: Beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned. Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose.
Thyrotoxicosis: Beta-adrenergic blockade may mask clinical signs of hyperthyroidism. Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm.
Renal Disease: Cumulative effects of the thiazides may develop in patients with impaired renal function. In such patients, thiazides may precipitate azotemia. In subjects with creatinine clearance less than 40 mL/min, the plasma half-life of bisoprolol fumarate is increased up to threefold, as compared to healthy subjects.
Hepatic Disease: ZIAC should be used with caution in patients with impaired hepatic function or progressive liver disease.

PRECAUTIONS

General: *Electrolyte and Fluid Balance Status:* Periodic determination of serum electrolytes should be performed, and patients should be observed for signs of fluid or electrolyte disturbances. Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Hypokalemia may develop. Hypokalemia and hypomagnesemia can provoke ventricular arrhythmias or sensitize or exaggerate the response of the heart to the toxic effects of digitalis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than salt administration, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice. *Parathyroid Disease:* Calcium excretion is decreased by thiazides, and pathologic changes in the parathyroid glands, with hypercalcemia and hypophosphatemia, have been observed in a few patients on prolonged thiazide therapy. *Hyperuricemia:* Hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics. Bisoprolol fumarate, alone or in combination with HCTZ, has been associated with increases in uric acid.
Drug Interactions: ZIAC may potentiate the action of other antihypertensive agents used concomitantly. ZIAC should not be combined with other beta-blocking agents. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZIAC be discontinued for several days before the withdrawal of clonidine.

ZIAC should be used with caution when myocardial depressants or inhibitors of AV conduction or antiarrhythmic agents are used concurrently.

Bisoprolol Fumarate: Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin and cimetidine. There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin.

While taking beta-blockers, patients with a history of severe anaphylactic reaction may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.

Hydrochlorothiazide: The following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics–potentiation of orthostatic hypotension may occur. Dosage adjustment of the antidiabetic drugs (oral agents and insulin) may be required. Other antihypertensive drugs–additive effect or potentiation. Cholestyramine and colestipol resins–single doses of cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption in the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroids, ACTH–intensified electrolyte depletion, particularly hypokalemia. Possible decreased response to pressor amines but not sufficient to preclude their use. Possible increased responsiveness to muscle relaxants, nondepolarizing. Generally, lithium should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. The administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.

In patients receiving thiazides, sensitivity reactions may occur with or without a history of allergy or bronchial asthma. Photosensitivity reactions and possible exacerbation or activation of systemic lupus erythematosus have been reported in patients receiving thiazides. The antihypertensive effects of thiazides may be enhanced in the post-sympathectomy patient.
Laboratory Test Interactions: Based on reports involving thiazides, ZIAC may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. Because it includes a thiazide, ZIAC should be discontinued before carrying out tests for parathyroid function (see **PRECAUTIONS**–*Parathyroid Disease*).

ADVERSE REACTIONS

ZIAC: Bisoprolol fumarate/H6.25 mg is well tolerated in most patients. Most adverse effects (AEs) have been mild and transient. In more than 65,000 patients treated worldwide with bisoprolol fumarate, occurrences of bronchospasm have been rare. Discontinuation rates for AEs were similar for B/H6.25 mg and placebo-treated patients.

In the United States, 252 patients received bisoprolol fumarate (2.5, 5, 10, or 40 mg)/H6.25 mg and 144 patients received placebo in two controlled trials. In Study 1, bisoprolol fumarate 5/H6.25 mg was administered for 4 weeks. In Study 2, bisoprolol fumarate 2.5, 10 or 40/H6.25 mg was administered for 12 weeks. All adverse experiences, whether drug-related or not, and drug-related adverse experiences in patients treated with B2.5-10/H6.25 mg, reported during comparable, 4 week treatment periods by at least 2% of bisoprolol fumarate/H6.25 mg-treated patients (plus additional selected adverse experiences) are presented in the following table:

ZIAC™ (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets

Body System/ Adverse Experience	% of Patients with Adverse Experiences*			
	All Adverse Experiences		Drug-related Adverse Experiences	
	Placebo† (n = 144) %	B2.5-40/H6.25† (n = 252) %	Placebo† (n = 144) %	B2.5-10/H6.25† (n = 221) %
Cardiovascular				
bradycardia	0.7	1.1	0.7	0.9
arrhythmia	1.4	0.4	0.0	0.0
peripheral ischemia	0.9	0.7	0.9	0.4
chest pain	0.7	1.8	0.7	0.9
Respiratory				
bronchospasm	0.0	0.0	0.0	0.0
cough	1.0	2.2	0.7	1.5
rhinitis	2.0	0.7	0.7	0.9
URI	2.3	2.1	0.0	0.0
Body as a Whole				
asthenia	0.0	0.0	0.0	0.0
fatigue	2.7	4.6	1.7	3.0
peripheral edema	0.7	1.1	0.7	0.9
Central Nervous System				
dizziness	1.8	5.1	1.8	3.2
headache	4.7	4.5	2.7	0.4
Musculoskeletal				
muscle cramps	0.7	1.2	0.7	1.1
myalgia	1.4	2.4	0.0	0.0
Psychiatric				
insomnia	2.4	1.1	2.0	1.2
somnolence	0.7	1.1	0.7	0.9
loss of libido	1.2	0.4	1.2	0.4
impotence	0.7	1.1	0.7	1.1
Gastrointestinal				
diarrhea	1.4	4.3	1.2	1.1
nausea	0.9	1.1	0.9	0.9
dyspepsia	0.7	1.2	0.7	0.9

*Averages adjusted to combine across studies.
†Combined across studies.

Other adverse experiences that have been reported with the individual components are listed below.
Bisoprolol Fumarate: In clinical trials worldwide, a variety of other AEs, in addition to those listed above, have been reported. While in many cases it is not known whether a causal relationship exists between bisoprolol and these AEs, they are listed to alert the physician to a possible relationship. *Central Nervous System:* Unsteadiness, vertigo, syncope, paresthesia, hyperesthesia, sleep disturbance/vivid dreams, depression, anxiety/restlessness, decreased concentration/memory. *Cardiovascular:* Palpitations and other rhythm disturbances, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain, congestive heart failure. *Gastrointestinal:* Gastric/epigastric/abdominal pain, peptic ulcer, gastritis, vomiting, constipation, dry mouth. *Musculoskeletal:* Arthralgia, muscle/joint pain, back/neck pain, twitching/tremor. *Skin:* Rash, acne, eczema, psoriasis, skin irritation, pruritus, purpura, flushing, sweating, alopecia, dermatitis, exfoliative dermatitis (very rarely). *Special Senses:* Visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing, earache, taste abnormalities. *Metabolic:* Gout. *Respiratory:* Asthma, bronchitis, dyspnea, pharyngitis, sinusitis. *Genitourinary:* Peyronie's disease (very rarely), cystitis, renal colic, polyuria. *General:* Malaise, edema, weight gain, angioedema.

In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects: *Central Nervous System:* Reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium. *Allergic:* Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. *Hematologic:* Agranulocytosis, thrombocytopenia. *Gastrointestinal:* Mesenteric arterial thrombosis and ischemic colitis. *Miscellaneous:* The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with bisoprolol fumarate during investigational use or extensive foreign marketing experience.
Hydrochlorothiazide: The following adverse experiences, in addition to those listed in the above table, have been reported with hydrochlorothiazide (generally with doses of 25 mg or greater). *General:* Weakness. *Central Nervous System:* Vertigo, paresthesia, restlessness. *Cardiovascular:* Orthostatic hypotension (may be potentiated by alcohol, barbiturates, or narcotics). *Gastrointestinal:* Anorexia, gastric irritation, cramping, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, cholecystitis, sialadenitis, dry mouth. *Musculoskeletal:* Muscle spasm. *Hypersensitive Reactions:* Purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions. *Special Senses:* Transient blurred vision, xanthopsia. *Metabolic:* Gout. *Genitourinary:* Sexual dysfunction, renal failure, renal dysfunction, interstitial nephritis.

LABORATORY ABNORMALITIES

ZIAC: Because of the low dose of hydrochlorothiazide in ZIAC, adverse metabolic effects with B/H6.25 mg are less frequent and of smaller magnitude than with HCTZ 25 mg.

Treatment with both beta-blockers and thiazide diuretics is associated with increases in uric acid. Mean increases in serum triglycerides were observed in patients treated with bisoprolol fumarate and hydrochlorothiazide 6.25 mg. Total cholesterol was generally unaffected, but small decreases in HDL cholesterol were noted.

Other laboratory abnormalities that have been reported with the individual components are listed below.
Bisoprolol Fumarate: In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding.

Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with bisoprolol fumarate treatment for 4 to 12 weeks, the incidence of concomitant elevations in SGOT and SGPT of between 1 to 2 times normal was 3.9%, compared to 2.5% for placebo. No patient had concomitant elevations greater than twice normal.

In the long-term, uncontrolled experience with bisoprolol fumarate treatment for 6-18 months, the incidence of one or more concomitant elevations in SGOT and SGPT of between 1-2 times normal was 6.2%. The incidence of multiple occurrence was 1.9%. For concomitant elevations in SGOT and SGPT of greater than twice normal, the incidence was 1.5%. The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with bisoprolol fumarate.

Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets. There have been occasional reports of eosinophilia. These were generally not of clinical importance and rarely resulted in discontinuation of bisoprolol fumarate.

As with other beta-blockers, ANA conversions have also been reported on bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy.
Hydrochlorothiazide: Hyperglycemia, glycosuria, hyperuricemia, hypokalemia and other electrolyte imbalances (see **PRECAUTIONS**), hyperlipidemia, hypercalcemia, leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic anemia have been associated with HCTZ therapy.

See **DOSAGE AND ADMINISTRATION** section in package insert for complete dosing and precautionary information.

Lederle

ADVANTUS PHARMACEUTICALS and
LEDERLE LABORATORIES DIVISION
American Cyanamid Company
Pearl River, NY 10965

Advantus™ Pharmaceuticals

REV. 3/93
L-32073-93

Under license of E. MERCK, Darmstadt, Germany



A PRACTICE THAT OFFERS THE WORLD

If you're a family physician looking for a professional life that keeps you attuned to high-tech medical advances and offers you financial rewards, opportunities for career development, excellent benefits and world travel, the Navy Medical Corps may be for you. As a Navy physician, you'll practice in a collegial environment where physicians support each other. You'll be a commissioned officer and a respected member of the Navy's prestigious health care delivery team.

You'll work in clinical settings in the United States and around the world with top professionals and state-of-the-art equipment and facilities. Through funded continuing education and specialty training, you'll have the opportunity to develop your full professional potential as well as the freedom to move from practice to research or teaching without losing seniority, salary level or retirement benefits.

You'll earn an excellent starting salary based on your credentials and years of experience, and federal law provides free medical liability protection to Navy physicians. You may also be entitled to special pay in addition to your regular salary and allowances. Navy benefits include 30 days of paid vacation earned each year, free medical and dental care, tax-free housing and food allowance, an excellent retirement system and opportunities for free travel to some of the most exotic and beautiful places in the world.

For more information, contact your local Navy Medical Programs officer, or if you'd like to talk to a Navy physician, call **1-800-USA-NAVY.** Ask for operator 10.

NAVY

YOU AND THE NAVY. FULL SPEED AHEAD.

Release the grip of tension headache



Non-scheduled* **Esgic plus tablets**

Butalbital 50mg (Warning: May be habit forming)
/Acetaminophen 500mg/Caffeine 40mg

Over 50% more analgesic power than the leading products in its class.

Well tolerated — Without aspirin-related side effects such as GI irritation and GI bleeding.[1-5] The most frequent adverse reactions are drowsiness and dizziness.

FOREST PHARMACEUTICALS, INC.
UAD LABORATORIES
St. Louis, Missouri 63045

Please see references and brief summary of full prescribing information on adjacent page.

*In most states.

U.S. Postal Service
STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION
(required by 39 U.S.C. 3685)

1. Title of Publication: JABFP The Journal of the American Board of Family Practice. 2. Publication No.: 002-036. 3. Date of filing: 09/25/94. 4. Frequency of issue: Monthly in Jan, Mar, May, July, Sep, and Nov. 5. No. of issues published annually: 6. 6. Annual subscription price: $35. 7. Complete mailing address of known office of publication: 2228 Young Drive, Lexington, KY 40505-4294. 8. Complete mailing address of the headquarters or general business offices of the publishers: 2228 Young Drive, Lexington, KY 40505-4294.

9. Full names and complete mailing addresses of the publisher, editor, and managing editor: Publisher: American Board of Family Practice, 2228 Young Drive, Lexington, KY 40505-4294. Editor: Paul R. Young, M.D., 2228 Young Drive, Lexington, KY 40505-4294. Managing Editor: Paul R. Young, M.D., 2228 Young Drive, Lexington, KY 40505-4294. 10. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.): American Board of Family Practice, 2228 Young Drive, Lexington, KY 40505-4294. 11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities (If there are none, so state: None.

12. For completion by nonprofit organizations authorized to mail at special rates (DMM Section 424.12 only). The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (1) has not changed during preceding 12 months.

	Average no. copies each issue during preceding 12 months	Actual no. copies of single issue published nearest to filing date
15. Extent and nature of circulation		
A. Total no. copies (net press run)	52,707	52,401
B. Paid circulation		
1. Sales through dealers and carriers, street vendors and counter sales	n/a	n/a
2. Mail subscription	42,243	41,732
C. Total paid circulation	42,243	41,372
D. Free distribution by mail, carrier, or other means, samples, complimentary, and other free copies	9,821	9,879
E. Free distribution outside the mail	none	none
F. Total free distribution	9,821	9,879
G. Total distribution	52,064	51,611
H. Copies not distributed		
1. Office use, left over, unaccounted, spoiled after printing	643	790
2. Return from news agents	n/a	n/a
I. Total	52,707	52,401
Percent paid and/or requested circulation	81%	80%

I certify that the statements made by me above are correct and complete.

Paul R. Young, M.D.
Executive Editor

References: 1. Benson GD. Hepatotoxicity following the therapeutic use of antipyretic analgesics. *Am J Med.* 1983;75(suppl 5A):85-93. 2. Jick H. Effects of aspirin and acetaminophen in gastro-intestinal hemorrhage. *Arch Intern Med.* 1981;141:316-321. 3. Mielke CH Jr. Comparative effects of aspirin and acetaminophen on hemostasis. *Arch Intern Med.* 1981;141:305-310. 4. Hansten PD. *Drug Interactions.* 5th ed. Philadelphia, PA: Lea & Febiger; 1985, p. 95. 5. Insel PA. Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. *The Pharmacological Basis of Therapeutics.* 8th ed. New York, NY: Pergamon Press; 1990:638-681.

ATTENTION

DIPLOMATES OF THE ABFP
ADDRESS CHANGE FORM



The Board prefers the use of *professional addresses*, because the address given will become your "address of record" with the Board and will be published in our Directory of Diplomates.

Current addresses for all Diplomates are necessary for communication from the Board relating to the Examinations, up-dated Recertification information, etc., as well as to ensure the receipt of *The Journal of the American Board of Family Practice*.

Name _____

Current Address	**New Address**
Street _____	Street _____
_____	_____
City/State _____	City/State _____
Zip Code _____	Zip Code _____

Effective Date of Change _____

Signature of Diplomate _____

ABFP Identification Number _____
(5-digit number above name on mailing label)

Year of Certification or Recertification _____

Return to: **Ann Stockham**
The American Board of Family Practice
2228 Young Drive
Lexington, KY 40505

NEW!

THUMZ'UP®

Some People Say... "You Can't Get Too Much Of A Good Thing."

I-Plus System
Humeral Fracture Brace™



ORFIZIP®
Knee Cast

ORFIZIP®
Body Jacket

NEW!



PLAST-O-FIT® Thermoplastic
Bandage For Immobilization

NEW!



ORFIZIP® Wrist Cast



Galveston Metacarpal Brace™



Cuff & Collar Sling



I-Plus System
Ulnar Fracture Brace™

We Agree, And We Feel Your Patients Will Too.

In 1987, Galveston Manufacturing introduced the Galveston Metacarpal Brace™. After over seven years of clinical use, the brace has proven successful in treating metacarpal shaft fractures. Galveston Manufacturing has continued serving the medical community, bringing you the latest quality fracture management products at affordable prices. So far this year we've introduced three new products to our line; the THUMZ'UP® functional thumb splint, the ORFIZIP® removable casting system and the PLAST-O-FIT® thermoplastic bandage for immobilization.

For ordering information or a product catalog, simply call 1-800-634-3309. These products will be displayed at the AAFP in Boston, booth #1114.

GALVESTON
MANUFACTURING
"Simple Solutions In Functional Bracing"

Just how powerful is it?

The vast majority of patients on PLENDIL receive prescriptions for 5 mg, once daily.*

PLENDIL provides a gradual onset of action for continuous 24-hour blood-pressure control in many patients.

And, PLENDIL is suited to a broad range of your hypertensive patients — including many with concomitant disorders, such as: hypercholesterolemia, diabetes, impaired renal function, COPD, or asthma.

PLENDIL. A highly effective calcium channel blocker for blood pressure control.

Generally well tolerated at usual doses.†

Plendil®

(felodipine) *Tablets, 5 mg, 10 mg*

Because you consider the whole patient.

*1993 IMS NDTI Prescription Data.

† Peripheral edema, generally mild, was the most common adverse event in clinical trials.

PLENDIL is contraindicated in patients who are hypersensitive to this product.

Please see brief summary of Prescribing Information on page following next page.

A/M GROUP
of MERCK & CO., Inc.


FRASER

BRIEF SUMMARY

TABLETS

PLENDIL®

(FELODIPINE)

EXTENDED-RELEASE TABLETS

INDICATIONS AND USAGE

PLENDIL* is indicated for the treatment of hypertension. PLENDIL may be used alone or concomitantly with other antihypertensive agents.

CONTRAINDICATIONS

PLENDIL is contraindicated in patients who are hypersensitive to this product.

PRECAUTIONS

General

Hypotension: Felodipine, like other calcium antagonists, may occasionally precipitate significant hypotension and rarely syncope. It may lead to reflex tachycardia which in susceptible individuals may precipitate angina pectoris. (See ADVERSE REACTIONS.)

Heart Failure: Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established. Caution therefore should be exercised when using PLENDIL in patients with heart failure or compromised ventricular function, particularly in combination with a beta blocker.

Elderly Patients or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function may have elevated plasma concentrations of felodipine and may therefore respond to lower doses of PLENDIL. These patients should have their blood pressure monitored closely during dosage adjustment of PLENDIL and should rarely require doses above 10 mg. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections of complete Prescribing Information.)

Peripheral Edema: Peripheral edema, generally mild and not associated with generalized fluid retention, was the most common adverse event in the clinical trials. The incidence of peripheral edema was both dose- and age-dependent. Frequency of peripheral edema ranged from about 10 percent in patients under 50 years of age taking 5 mg daily to about 30 percent in those over 60 years of age taking 20 mg daily. This adverse effect generally occurs within 2-3 weeks of the initiation of treatment.

Information for Patients

Patients should be instructed to take PLENDIL whole and not to crush or chew the tablets. They should be told that mild gingival hyperplasia (gum swelling) has been reported. Good dental hygiene decreases its incidence and severity.

NOTE: As with many other drugs, certain advice to patients being treated with PLENDIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions

Beta-Blocking Agents: A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine. The AUC and C_{max} of metoprolol, however, were increased approximately 31 and 38 percent, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

Cimetidine: In healthy subjects pharmacokinetic studies showed an approximately 50 percent increase in the area under the plasma concentration time curve (AUC) as well as the C_{max} of felodipine when given concomitantly with cimetidine. It is anticipated that a clinically significant interaction may occur in some hypertensive patients. Therefore, it is recommended that low doses of PLENDIL be used when given concomitantly with cimetidine.

Digoxin: When given concomitantly with felodipine the peak plasma concentration of digoxin was significantly increased. There was, however, no significant change in the AUC of digoxin.

Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately six percent of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

Other Concomitant Therapy: In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.

Interaction with Food: See CLINICAL PHARMACOLOGY, *Pharmacokinetics and Metabolism* section of complete Prescribing Information.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year carcinogenicity study in rats fed felodipine at doses of 7.7, 23.1 or 69.3 mg/kg/day (up to 28 times** the maximum recommended human dose on a mg/m² basis), a dose related increase in the incidence of benign interstitial cell tumors of the testes (Leydig cell tumors) was observed in treated male rats. These tumors were not observed in a similar study in mice at doses up to 138.6 mg/kg/day (28 times** the maximum recommended human dose on a mg/m² basis). Felodipine, at the doses employed in the two-year rat study, has been shown to lower testicular testosterone and to produce a corresponding increase in serum luteinizing hormone in rats. The Leydig cell tumor development is possibly secondary to these hormonal effects which have not been observed in man.

In this same rat study a dose related increase in the incidence of focal squamous cell hyperplasia compared to control was observed in the esophageal groove of male and female rats in all dose groups. No other drug-related esophageal or gastric pathology was observed in the rats or with chronic administration in mice and dogs. The latter species, like man, has no anatomical structure comparable to the esophageal groove.

Felodipine was not carcinogenic when fed to mice at doses of up to 138.6 mg/kg/day (28 times** the maximum recommended human dose on a mg/m² basis) for periods of up to 80 weeks in males and 99 weeks in females.

Felodipine did not display any mutagenic activity *in vitro* in the Ames microbial mutagenicity test or in the mouse lymphoma forward mutation assay. No clastogenic potential was seen *in vivo* in the mouse micronucleus test at oral doses up to 2500 mg/kg (506 times** the maximum recommended human dose on a mg/m² basis) or *in vitro* in a human lymphocyte chromosome aberration assay.

A fertility study in which male and female rats were administered doses of 3.8, 9.6 or 26.9 mg/kg/day showed no significant effect of felodipine on reproductive performance.

Pregnancy

Pregnancy Category C

Teratogenic Effects. Studies in pregnant rabbits administered doses of 0.46, 1.2, 2.3 and 4.6 mg/kg/day (from 0.4 to 4 times** the maximum recommended human dose on a mg/m² basis) showed digital anomalies consisting of reduction in size and degree of ossification of the terminal phalanges in the fetuses. The frequency and severity of the changes appeared dose related and were noted even at the lowest dose. These changes have been shown to occur with other members of the dihydropyridine class and are possibly a result of compromised uterine blood flow. Similar fetal anomalies were not observed in rats given felodipine.

In a teratology study in cynomolgus monkeys no reduction in the size of the terminal phalanges was observed but an abnormal position of the distal phalanges was noted in about 40 percent of the fetuses.

Nonteratogenic Effects: A prolongation of parturition with difficult labor and an increased frequency of fetal and early postnatal deaths were observed in rats administered doses of 9.6 mg/kg/day (4 times** the maximum human dose on a mg/m² basis) and above.

Significant enlargement of the mammary glands in excess of the normal enlargement for pregnant rabbits was found with doses greater than or equal to 1.2 mg/kg/day (equal to the maximum human dose on a mg/m² basis). This effect occurred only in pregnant rabbits and regressed during lactation. Similar changes in the mammary glands were not observed in rats or monkeys.

There are no adequate and well-controlled studies in pregnant women. If felodipine is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus, possible digital anomalies of the infant, and the potential effects of felodipine on labor and delivery, and on the mammary glands of pregnant females.

Nursing Mothers

It is not known whether this drug is secreted in human milk and because of the potential for serious adverse reactions from felodipine in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

In controlled studies in the United States and overseas approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation.

The most common clinical adverse experiences reported with PLENDIL (Felodipine) administered as monotherapy in all settings and with all dosage forms of felodipine were peripheral edema and headache. Peripheral edema was generally mild, but it was age- and dose-related and resulted in discontinuation of therapy in about 4 percent of the enrolled patients. Discontinuation of therapy due to any clinical adverse experience occurred in about 9 percent of the patients receiving PLENDIL, principally for peripheral edema, headache, or flushing.

Adverse experiences that occurred with an incidence of 1.5 percent or greater during monotherapy with PLENDIL without regard to causality are compared to placebo in the table below.

Percent of Patients with Adverse Effects in Controlled Trials of PLENDIL as Monotherapy (incidence of discontinuations shown in parentheses)

Adverse Effect	PLENDIL% N = 730	Placebo % N = 283
Peripheral Edema	22.3 (4.2)	3.5
Headache	18.6 (2.1)	10.6
Flushing	6.4 (1.0)	1.1
Dizziness	5.8 (0.8)	3.2
Upper Respiratory Infection	5.5 (0.1)	1.1
Asthenia	4.7 (0.1)	2.8
Cough	2.9 (0.0)	0.4
Paresthesia	2.5 (0.1)	1.8
Dyspepsia	2.3 (0.0)	1.4
Chest Pain	2.1 (0.1)	1.4
Nausea	1.9 (0.8)	1.1
Muscle Cramps	1.9 (0.0)	1.1
Palpitation	1.8 (0.5)	2.5
Abdominal Pain	1.8 (0.3)	1.1
Constipation	1.6 (0.1)	1.1
Diarrhea	1.6 (0.1)	1.1
Pharyngitis	1.6 (0.0)	0.4
Rhinorrhea	1.6 (0.0)	0.0
Back Pain	1.6 (0.0)	1.1
Rash	1.5 (0.1)	1.1

In the two dose response studies using PLENDIL as monotherapy the following table describes the incidence (percent) of adverse experiences that were dose related. The incidence of discontinuations due to these adverse experiences are shown in parentheses.

Adverse Effect	Placebo N = 121	2.5 mg N = 71	5.0 mg N = 72	10.0 mg N = 123	20 mg N = 50
Peripheral Edema	2.5 (1.6)	1.4 (0.0)	13.9 (2.8)	19.5 (2.4)	36.0 (10.0)
Palpitation	0.8 (0.8)	1.4 (0.0)	0.0 (0.0)	2.4 (0.8)	12.0 (8.0)
Headache	12.4 (0.0)	11.3 (1.4)	11.1 (0.0)	18.7 (4.1)	28.0 (18.0)
Flushing	0.0 (0.0)	4.2 (0.0)	2.8 (0.0)	8.1 (0.8)	20.0 (8.0)

In addition, adverse experiences that occurred in 0.5 up to 1.5 percent of patients who received PLENDIL (Felodipine) in all controlled clinical studies (listed in order of decreasing severity within each category) and serious adverse events that occurred at a lower rate or were found during marketing experience (those lower rate events are in italics) were: *Body as a Whole:* Facial edema, warm sensation; *Cardiovascular:* Tachycardia, *myocardial infarction, hypotension, syncope, angina pectoris,* arrhythmia; *Digestive:* Vomiting, dry mouth, flatulence; *Hematologic: Anemia; Musculoskeletal:* Arthralgia, arm pain, knee pain, leg pain, foot pain, hip pain, myalgia; *Nervous/Psychiatric:* Depression, anxiety disorders, insomnia, irritability, nervousness, somnolence; *Respiratory:* Bronchitis, influenza, sinusitis, dyspnea, epistaxis, respiratory infection, sneezing; *Skin:* Contusion, erythema, urticaria; *Urogenital:* Decreased libido, impotence, urinary frequency, urinary urgency, dysuria.

Felodipine, as an immediate release formulation, has also been studied as monotherapy in 680 patients with hypertension in U.S. and overseas controlled clinical studies. Other adverse experiences not listed above and with an incidence of 0.5 percent or greater include: *Body as a Whole:* Fatigue; *Digestive:* Gastrointestinal pain; *Musculoskeletal:* Arthritis, local weakness, neck pain, shoulder pain, ankle pain; *Nervous/Psychiatric:* Tremor; *Respiratory:* Rhinitis; *Skin:* Hyperhidrosis, pruritus; *Special Senses:* Blurred vision, tinnitus; *Urogenital:* Nocturia.

Gingival Hyperplasia: Gingival hyperplasia, usually mild, occurred in <0.5 percent of patients in controlled studies. This condition may be avoided or may regress with improved dental hygiene. (See PRECAUTIONS, *Information for Patients.*)

Clinical Laboratory Test Findings

Serum Electrolytes: No significant effects on serum electrolytes were observed during short- and long-term therapy.

Serum Glucose: No significant effects on fasting serum glucose were observed in patients treated with PLENDIL in the U.S. controlled study.

Liver Enzymes: One of two episodes of elevated serum transaminases decreased once drug was discontinued in clinical studies; no follow-up was available for the other patient.

OVERDOSAGE

Oral doses of 240 mg/kg and 264 mg/kg in male and female mice, respectively and 2390 mg/kg and 2250 mg/kg in male and female rats, respectively, caused significant lethality.

In a suicide attempt, one patient took 150 mg felodipine together with 15 tablets each of atenolol and spironolactone and 20 tablets of nitrazepam. The patient's blood pressure and heart rate were normal on admission to hospital; he subsequently recovered without significant sequelae.

Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly bradycardia.

If severe hypotension occurs, symptomatic treatment should be instituted. The patient should be placed supine with the legs elevated. The administration of intravenous fluids may be useful to treat hypotension due to overdosage with calcium antagonists. In case of accompanying bradycardia, atropine (0.5-1 mg) should be administered intravenously. Sympathomimetic drugs may also be given if the physician feels they are warranted.

It has not been established whether felodipine can be removed from the circulation by hemodialysis.

DOSAGE AND ADMINISTRATION

The recommended initial dose is 5 mg once a day. Therapy should be adjusted individually according to patient response, generally at intervals of not less than two weeks. The usual dosage range is 5-10 mg once daily. The maximum recommended daily dose is 20 mg once a day. That dose in clinical trials showed an increased blood pressure response but a large increase in the rate of peripheral edema and other vasodilatory adverse events (see ADVERSE REACTIONS). Modification of the recommended dosage is usually not required in patients with renal impairment.

PLENDIL should be swallowed whole and not crushed or chewed.

Use in the Elderly or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function, because they may develop higher plasma concentrations of felodipine, should have their blood pressure monitored closely during dosage adjustment (see PRECAUTIONS). In general, doses above 10 mg should not be considered in these patients.

A/M GROUP
OF MERCK & CO., INC.

For more detailed information, consult your Astra/Merck Specialist or see complete Prescribing Information.

Astra/Merck Group of Merck & Co., Inc.
725 Chesterbrook Boulevard, Wayne, PA 19087

PLENDIL is a product of Astra/Merck Research

7650203 3000-04/5/93/12-09/Ppl

* Registered trademark of AB Astra

** Based on patient weight of 50 kg

75% of primary care physicians have treated patients with HIV infection.

Do you have the information you need?

Every month, *AIDS Clinical Care* brings you the latest clinically relevant information in a concise, easy-to-read newsletter.

Feature articles written by leading AIDS clinicians provide hands-on information about the management of HIV-related diseases. Topics include:

- AIDS/HIV Clinical Trial Updates
- Antiretroviral Therapy Controversies
- Treating and Preventing Opportunistic Infections
- HIV Infection in Women
- NIH Recommendations
- Pediatric AIDS
- Drug Interactions
- Psychosocial Issues
- Nutrition in HIV

The new **Case History** column answers clinical questions on the complex, overlapping manifestations of HIV infection by presenting actual case histories with diagnoses and patient follow-up.

Research Notes summarize and comment on the most relevant articles from the medical literature. **Charts and tables** clearly show clinical presentations, diagnostic methods, treatment regimens, and epidemiologic trends.

EDITOR

Deborah J. Cotton, MD, MPH

Infectious Disease Unit, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School; Assistant Professor of Health Policy and Management, Harvard School of Public Health, Boston.



Subscribe today. Simply fill out the coupon, or order by FAX: (617) 893-0413

❑ YES, please start my subscription to AIDS Clinical Care.

I will receive 12 monthly issues delivered first class for the special price of $89.

❑ Payment enclosed* ❑ Bill me

❑ Charge my credit card ❑ VISA ❑ MasterCard ❑ AmEx

Card #_____ Exp Date_____

Signature _____

Name_____
(Please print)

Address_____

City_____ State_____ Zip _____

Specialty:_____

Credit card orders, call toll-free
1-800-843-6356

Mail to: AIDS Clinical Care,
PO Box 9085, Waltham, MA 02254-9085

* Make check payable to AIDS Clinical Care.
Allow 4-6 weeks for delivery.

Publishing Division of the Massachusetts Medical Society

Founded in Cooperation with the American Foundation for AIDS Research (AmFAR).

ISSN: 1043-1543

SAMF2

Just how powerful is it?

The vast majority of patients on PLENDIL receive prescriptions for 5 mg, once daily.*

PLENDIL provides a gradual onset of action for continuous 24-hour blood-pressure control in many patients.

And, PLENDIL is suited to a broad range of your hypertensive patients — including many with concomitant disorders, such as: hypercholesterolemia, diabetes, impaired renal function, COPD, or asthma.

PLENDIL. A highly effective calcium channel blocker for blood pressure control.

Generally well tolerated at usual doses.†

Plendil®

(felodipine) Tablets, 5 mg, 10 mg

Because you consider the whole patient.

*1993 IMS NDTI Prescription Data.

† Peripheral edema, generally mild, was the most common adverse event in clinical trials.

PLENDIL is contraindicated in patients who are hypersensitive to this product.

Please see brief summary of Prescribing Information on page following next page.

A/M GROUP
of MERCK & CO. Inc.



BRIEF SUMMARY

TABLETS
PLENDIL®
(FELODIPINE)
EXTENDED RELEASE TABLETS

INDICATIONS AND USAGE

PLENDIL* is indicated for the treatment of hypertension. PLENDIL may be used alone or concomitantly with other antihypertensive agents.

CONTRAINDICATIONS

PLENDIL is contraindicated in patients who are hypersensitive to this product.

PRECAUTIONS

General

Hypotension: Felodipine, like other calcium antagonists, may occasionally precipitate significant hypotension and rarely syncope. It may lead to reflex tachycardia which in susceptible individuals may precipitate angina pectoris. (See ADVERSE REACTIONS.)

Heart Failure: Although acute hemodynamic studies in a small number of patients with NYHA Class II or III heart failure treated with felodipine have not demonstrated negative inotropic effects, safety in patients with heart failure has not been established. Caution therefore should be exercised when using PLENDIL in patients with heart failure or compromised ventricular function, particularly in combination with a beta blocker.

Elderly Patients or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function may have elevated plasma concentrations of felodipine and may therefore respond to lower doses of PLENDIL. These patients should have their blood pressure monitored closely during dosage adjustment of PLENDIL and should rarely require doses above 10 mg. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections of complete Prescribing Information.)

Peripheral Edema: Peripheral edema, generally mild and not associated with generalized fluid retention, was the most common adverse event in the clinical trials. The incidence of peripheral edema was both dose- and age-dependent. Frequency of peripheral edema ranged from about 10 percent in patients under 50 years of age taking 5 mg daily to about 30 percent in those over 60 years of age taking 20 mg daily. This adverse effect generally occurs within 2–3 weeks of the initiation of treatment.

Information for Patients

Patients should be instructed to take PLENDIL whole and not to crush or chew the tablets. They should be told that mild gingival hyperplasia (gum swelling) has been reported. Good dental hygiene decreases its incidence and severity.

NOTE: As with many other drugs, certain advice to patients being treated with PLENDIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions

Beta-Blocking Agents: A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine. The AUC and C_{max} of metoprolol, however, were increased approximately 31 and 38 percent, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

Cimetidine: In healthy subjects pharmacokinetic studies showed an approximately 50 percent increase in the area under the plasma concentration time curve (AUC) as well as the C_{max} of felodipine when given concomitantly with cimetidine. It is anticipated that a clinically significant interaction may occur in some hypertensive patients. Therefore, it is recommended that low doses of PLENDIL be used when given concomitantly with cimetidine.

Digoxin: When given concomitantly with felodipine the peak plasma concentration of digoxin was significantly increased. There was, however, no significant change in the AUC of digoxin.

Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately six percent of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

Other Concomitant Therapy: In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.

Interaction with Food: See CLINICAL PHARMACOLOGY, *Pharmacokinetics and Metabolism* section of complete Prescribing Information.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year carcinogenicity study in rats fed felodipine at doses of 7.7, 23.1 or 69.3 mg/kg/day (up to 28 times the maximum recommended human dose on a mg/m² basis), a dose-related increase in the incidence of benign interstitial cell tumors of the testes (Leydig cell tumors) was observed in treated male rats. These tumors were not observed in a similar study in mice at doses up to 138.6 mg/kg/day (28 times the maximum recommended human dose on a mg/m² basis). Felodipine, at the doses employed in the two-year rat study, has been shown to lower testicular testosterone and to produce a corresponding increase in serum luteinizing hormone in rats. The Leydig cell tumor development is possibly secondary to these hormonal effects which have not been observed in man.

In this same rat study a dose-related increase in the incidence of focal squamous cell hyperplasia compared to control was observed in the esophageal groove of male and female rats in all dose groups. No other drug-related esophageal or gastric pathology was observed in the rats or with chronic administration in mice and dogs. The latter species, like man, has no anatomical structure comparable to the esophageal groove.

Felodipine was not carcinogenic when fed to mice at doses of up to 138.6 mg/kg/day (28 times the maximum recommended human dose on a mg/m² basis) for periods of up to 80 weeks in males and 99 weeks in females.

Felodipine did not display any mutagenic activity *in vitro* in the Ames microbial mutagenicity test or in the mouse lymphoma forward mutation assay. No clastogenic potential was seen *in vivo* in the mouse micronucleus test at oral doses up to 2500 mg/kg (506 times the maximum recommended human dose on a mg/m² basis) or *in vitro* in a human lymphocyte chromosome aberration assay.

A fertility study in which male and female rats were administered doses of 3.8, 9.6 or 26.9 mg/kg/day showed no significant effect of felodipine on reproductive performance.

Pregnancy

Pregnancy Category C

Teratogenic Effects. Studies in pregnant rabbits administered doses of 0.46, 1.2, 2.3 and 4.6 mg/kg/day (from 0.4 to 4 times the maximum recommended human dose on a mg/m² basis) showed digital anomalies consisting of reduction in size and degree of ossification of the terminal phalanges in the fetuses. The frequency and severity of the changes appeared dose related and were noted even at the lowest dose. These changes have been shown to occur with other members of the dihydropyridine class and are possibly a result of compromised uterine blood flow. Similar fetal anomalies were not observed in rats given felodipine.

In a teratology study in cynomolgus monkeys no reduction in the size of the terminal phalanges was observed but an abnormal position of the distal phalanges was noted in about 40 percent of the fetuses.

Nonteratogenic Effects. A prolongation of parturition with difficult labor and an increased frequency of fetal and early postnatal deaths were observed in rats administered doses of 9.6 mg/kg/day (4 times the maximum human dose on a mg/m² basis) and above.

Significant enlargement of the mammary glands in excess of the normal enlargement for pregnant rabbits was found with doses greater than or equal to 1.2 mg/kg/day (equal to the maximum human dose on a mg/m² basis). This effect occurred only in pregnant rabbits and regressed during lactation. Similar changes in the mammary glands were not observed in rats or monkeys.

There are no adequate and well-controlled studies in pregnant women. If felodipine is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus, possible digital anomalies of the infant, and the potential effects of felodipine on labor and delivery, and on the mammary glands of pregnant females.

Nursing Mothers

It is not known whether this drug is secreted in human milk and because of the potential for serious adverse reactions from felodipine in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

In controlled studies in the United States and overseas approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation.

The most common clinical adverse experiences reported with PLENDIL* (Felodipine) administered as monotherapy in all settings and with all dosage forms of felodipine were peripheral edema and headache. Peripheral edema was generally mild, but it was age- and dose-related and resulted in discontinuation of therapy in about 4 percent of the enrolled patients. Discontinuation of therapy due to any clinical adverse experience occurred in about 9 percent of the patients receiving PLENDIL, principally for peripheral edema, headache, or flushing.

Adverse experiences that occurred with an incidence of 1.5 percent or greater during monotherapy with PLENDIL without regard to causality are compared to placebo in the table below.

Percent of Patients with Adverse Effects in Controlled Trials of PLENDIL as Monotherapy (incidence of discontinuations shown in parentheses)

Adverse Effect	PLENDIL% N = 730	Placebo % N = 283
Peripheral Edema	22.3 (4.2)	3.5
Headache	18.6 (2.1)	10.6
Flushing	6.4 (1.0)	1.1
Dizziness	5.8 (0.8)	3.2
Upper Respiratory Infection	5.5 (0.1)	1.1
Asthenia	4.7 (0.1)	2.8
Cough	2.9 (0.0)	0.4
Paresthesia	2.5 (0.1)	1.8
Dyspepsia	2.3 (0.0)	1.4
Chest Pain	2.1 (0.1)	1.4
Nausea	1.9 (0.8)	1.1
Muscle Cramps	1.9 (0.0)	1.1
Palpitation	1.8 (0.5)	2.5
Abdominal Pain	1.8 (0.3)	1.1
Constipation	1.6 (0.1)	1.1
Diarrhea	1.6 (0.1)	1.1
Pharyngitis	1.6 (0.0)	0.4
Rhinorrhea	1.6 (0.0)	0.0
Back Pain	1.6 (0.0)	1.1
Rash	1.5 (0.1)	1.1

In the two dose response studies using PLENDIL as monotherapy the following table describes the incidence (percent) of adverse experiences that were dose related. The incidence of discontinuations due to these adverse experiences are shown in parentheses.

Adverse Effect	Placebo N = 121	2.5 mg N = 71	5.0 mg N = 72	10.0 mg N = 123	20 mg N = 50
Peripheral Edema	2.5 (1.6)	1.4 (0.0)	13.9 (2.8)	19.5 (2.4)	36.0 (10.0)
Palpitation	0.8 (0.8)	1.4 (0.0)	0.0 (0.0)	2.4 (0.8)	12.0 (8.0)
Headache	12.4 (0.0)	11.3 (1.4)	11.1 (0.0)	18.7 (4.1)	28.0 (18.0)
Flushing	0.0 (0.0)	4.2 (0.0)	2.8 (0.0)	8.1 (0.8)	20.0 (8.0)

In addition, adverse experiences that occurred in 0.5 up to 1.5 percent of patients who received PLENDIL (Felodipine) in all controlled clinical studies (listed in order of decreasing severity within each category) and serious adverse events that occurred at a lower rate or were found during marketing experience (those lower rate events are in italics) were: *Body as a Whole:* Facial edema, warm sensation; *Cardiovascular:* Tachycardia, *myocardial infarction, hypotension, syncope, angina pectoris,* arrhythmia; *Digestive:* Vomiting, dry mouth, flatulence; *Hematologic: Anemia; Musculoskeletal:* Arthralgia, arm pain, knee pain, leg pain, foot pain, hip pain, myalgia; *Nervous/Psychiatric:* Depression, anxiety disorders, insomnia, irritability, nervousness, somnolence; *Respiratory:* Bronchitis, influenza, sinusitis, dyspnea, epistaxis, respiratory infection, sneezing; *Skin:* Contusion, erythema, urticaria; *Urogenital:* Decreased libido, impotence, urinary frequency, urinary urgency, dysuria.

Felodipine, as an immediate release formulation, has also been studied as monotherapy in 680 patients with hypertension in U.S. and overseas controlled clinical studies. Other adverse experiences not listed above and with an incidence of 0.5 percent or greater include: *Body as a Whole:* Fatigue; *Digestive:* Gastrointestinal pain; *Musculoskeletal:* Arthritis, local weakness, neck pain, shoulder pain, ankle pain; *Nervous/Psychiatric:* Tremor; *Respiratory:* Rhinitis; *Skin:* Hyperhidrosis, pruritus; *Special Senses:* Blurred vision, tinnitus; *Urogenital:* Nocturia.

Gingival Hyperplasia: Gingival hyperplasia, usually mild, occurred in < 0.5 percent of patients in controlled studies. This condition may be avoided or may regress with improved dental hygiene. (See PRECAUTIONS, *Information for Patients.*)

Clinical Laboratory Test Findings

Serum Electrolytes: No significant effects on serum electrolytes were observed during short- and long-term therapy.

Serum Glucose: No significant effects on fasting serum glucose were observed in patients treated with PLENDIL in the U.S. controlled study.

Liver Enzymes: One of two episodes of elevated serum transaminases decreased once drug was discontinued in clinical studies; no follow-up was available for the other patient.

OVERDOSAGE

Oral doses of 240 mg/kg and 264 mg/kg in male and female mice, respectively and 2390 mg/kg and 2250 mg/kg in male and female rats, respectively, caused significant lethality.

In a suicide attempt, one patient took 150 mg felodipine together with 15 tablets each of atenolol and spironolactone and 20 tablets of nitrazepam. The patient's blood pressure and heart rate were normal on admission to hospital; he subsequently recovered without significant sequelae.

Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly bradycardia.

If severe hypotension occurs, symptomatic treatment should be instituted. The patient should be placed supine with the legs elevated. The administration of intravenous fluids may be useful to treat hypotension due to overdosage with calcium antagonists. In case of accompanying bradycardia, atropine (0.5–1 mg) should be administered intravenously. Sympathomimetic drugs may also be given if the physician feels they are warranted.

It has not been established whether felodipine can be removed from the circulation by hemodialysis.

DOSAGE AND ADMINISTRATION

The recommended initial dose is 5 mg once a day. Therapy should be adjusted individually according to patient response, generally at intervals of not less than two weeks. The usual dosage range is 5–10 mg once daily. The maximum recommended daily dose is 20 mg once a day. That dose in clinical trials showed an increased blood pressure response but a large increase in the rate of peripheral edema and other vasodilatory adverse events (see ADVERSE REACTIONS). Modification of the recommended dosage is usually not required in patients with renal impairment.

PLENDIL should be swallowed whole and not crushed or chewed.

Use in the Elderly or Patients with Impaired Liver Function: Patients over 65 years of age or patients with impaired liver function, because they may develop higher plasma concentrations of felodipine, should have their blood pressure monitored closely during dosage adjustment (see PRECAUTIONS). In general, doses above 10 mg should not be considered in these patients.

A/M GROUP
OF MERCK & CO., INC.

For more detailed information, consult your Astra/Merck Specialist or see complete Prescribing Information.
Astra/Merck Group of Merck & Co., Inc.
725 Chesterbrook Boulevard, Wayne, PA 19087

PLENDIL is a product of Astra/Merck Research.

7650203 3000-04/5/9 3/12 09/Ppl

® Registered trademark of AB Astra
* Based on patient weight of 50 kg

AMBIEN®
(ZOLPIDEM TARTRATE) C-IV
5-MG & 10-MG TABLETS

From a unique chemical class of non-benzodiazepine sleep agents



More sleep

Total sleep time is significantly increased compared with placebo. Patients fall asleep quickly; generally within 20 to 30 minutes.[1-3]

Better sleep

Awakenings were reduced, compared to placebo.

Through the night

No evidence of increased wakefulness during the last third of the night. Normal sleep stages are generally preserved[1] (clinical significance unknown).

With no objective evidence of tolerance or rebound insomnia

In studies of up to 35 consecutive nights at recommended doses.[1,2]

Favorable safety and tolerability profile

Adverse events with dosages of ≤ 10 mg that were statistically significant vs placebo

Short-term: ≤10 nights		Long-term: 28 to 35 nights	
drowsiness	2%	dizziness	5%
dizziness	1%	drugged feelings	3%
diarrhea	1%		



AMBIEN®
(ZOLPIDEM TARTRATE) C-IV 5-MG & 10-MG TABLETS

In the short-term treatment of insomnia

First in a unique chemical class of non-benzodiazepine sleep agents

Please see references and brief summary of prescribing information on the last page of this advertisement.

References: 1. Data on file. Searle. 2. Vorpe G, Scharf M, Walsh J, et al. Effects of chronically administered zolpidem on the sleep of healthy insomniacs. *Sleep Research* 1989;18:80. Abstract. 3. Walsh JK, Schweitzer PK, Sugerman JL, et al. Transient insomnia associated with a 3-hour phase advance of sleep time and treatment with zolpidem. *J Clin Psychopharmacol* 1990;10:184-189.

AMBIEN
(ZOLPIDEM TARTRATE) C-IV
5 MG & 10 MG TABLETS

BRIEF SUMMARY

INDICATIONS AND USAGE

Ambien (zolpidem tartrate) is indicated for the short-term treatment of insomnia. Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are to be taken for more than 2 to 3 weeks.

Ambien should not be prescribed in quantities exceeding a 1-month supply (see *Warnings*).

CONTRAINDICATIONS

None known.

WARNINGS

Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness which should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including Ambien. Because some of the important adverse effects of Ambien appear to be dose related (see *Precautions* and *Dosage and Administration*), it is important to use the smallest possible effective dose, especially in the elderly.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (eg, aggressiveness and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Amnesia and other neuropsychiatric symptoms may occur unpredictably. In primarily depressed patients, worsening of depression, including suicidal thinking, has been reported in association with the use of sedative/hypnotics.

It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above are drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs (see *Drug Abuse and Dependence*).

Ambien, like other sedative/hypnotic drugs, has CNS-depressant effects. Due to the rapid onset of action, Ambien should only be ingested immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of Ambien. Ambien showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when Ambien is administered with such agents because of the potentially additive effects.

PRECAUTIONS

General

Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended Ambien dosage is 5 mg in such patients (see *Dosage and Administration*) to decrease the possibility of side effects. These patients should be closely monitored.

Use in patients with concomitant illness: Clinical experience with Ambien in patients with concomitant systemic illness is limited. Caution is advisable in using Ambien in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Although preliminary studies did not reveal respiratory depressant effects at hypnotic doses of Ambien in normals, precautions should be observed if Ambien is prescribed to patients with compromised respiratory function, since sedative/hypnotics have the capacity to depress respiratory drive. Post-marketing reports of respiratory insufficiency, most of which involved patients with pre-existing respiratory impairment, have been received. Data in end-stage renal failure patients repeatedly treated with Ambien did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored (see *Pharmacokinetics*). A study in subjects with hepatic impairment did reveal prolonged elimination in this group; therefore, treatment should be initiated with 5 mg in patients with hepatic compromise, and they should be closely monitored.

Use in depression: As with other sedative/hypnotic drugs, Ambien should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

Information for patients: Patient information is printed in the complete prescribing information and is available in pads for distribution to patients.

Laboratory tests: There are no specific laboratory tests recommended.

Drug interactions

CNS-active drugs: Ambien was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.

An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated.

Since the systematic evaluations of Ambien in combination with other CNS-active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of zolpidem.

Other drugs: A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem. Zolpidem had no effect on digoxin kinetics and did not affect prothrombin time when given with warfarin in normal subjects. Zolpidem's sedative/hypnotic effect was reversed by flumazenil; however, no significant alterations in zolpidem pharmacokinetics were found.

Drug/Laboratory test interactions: Zolpidem is not known to interfere with commonly employed clinical laboratory tests.

Carcinogenesis, mutagenesis, impairment of fertility

Carcinogenesis: Zolpidem was administered to rats and mice for 2 years at dietary dosages of 4, 18, and 80 mg/kg/day. In mice, these doses are 26 to 520 times or 2 to 35 times the maximum 10-mg human dose on a mg/kg or mg/m² basis, respectively. In rats these doses are 43 to 876 times or 6 to 115 times the maximum 10-mg human dose on a mg/kg or mg/m² basis, respectively. No evidence of carcinogenic potential was observed in mice. Renal liposarcomas were seen in 4/100 rats (3 males, 1 female) receiving 80 mg/kg/day and a renal lipoma was observed in one male rat at the 18 mg/kg/day dose. Incidence rates of lipoma and liposarcoma for zolpidem were comparable to those seen in historical controls and the tumor findings are thought to be a spontaneous occurrence.

Mutagenesis: Zolpidem did not have mutagenic activity in several tests including the Ames test, genotoxicity in mouse lymphoma cells in vitro, chromosomal aberrations in cultured human lymphocytes, unscheduled DNA synthesis in rat hepatocytes in vitro, and the micronucleus test in mice.

Impairment of fertility: In a rat reproduction study, the high dose (100 mg base/kg) of zolpidem resulted in irregular estrus cycles and prolonged precoital intervals, but there was no effect on male or female fertility after daily oral doses of 4 to 100 mg base/kg or 5 to 130 times the recommended human dose in mg/m². No effects on any other fertility parameters were noted.

Pregnancy

Category B. Studies to assess the effects of zolpidem on human reproduction and development have not been conducted.

Teratology studies were conducted in rats and rabbits.

In rats, adverse maternal and fetal effects occurred at 20 and 100 mg base/kg and included dose-related maternal lethargy and ataxia and a dose-related trend to incomplete ossification of fetal skull bones.

In rabbits, dose-related maternal sedation and decreased weight gain occurred at all doses tested. At the high dose, 16 mg base/kg, there was an increase in postimplantation fetal loss and underossification of sternebrae in viable fetuses.

This drug should be used during pregnancy only if clearly needed.

Nonteratogenic effects: Studies to assess the effects on children whose mothers took zolpidem during pregnancy have not been conducted. However, children born of mothers taking sedative/hypnotic drugs may be at some risk for withdrawal symptoms from the drug during the postnatal period. In addition, neonatal flaccidity has been reported in infants born of mothers who received sedative/hypnotic drugs during pregnancy.

Labor and delivery: Ambien has no established use in labor and delivery.

Nursing mothers: Studies in lactating mothers indicate that between 0.004 and 0.019% of the total administered dose is excreted into milk, but the effect of zolpidem on the infant is unknown.

The use of Ambien in nursing mothers is not recommended.

Safety and effectiveness in children below the age of 18 have not been established.

ADVERSE REACTIONS

Associated with discontinuation of treatment: Approximately 4% of 1,701 patients who received zolpidem at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials discontinued treatment because of an adverse clinical event. Events most commonly associated with discontinuation from U.S. trials were daytime drowsiness (0.5%), dizziness (0.4%), headache (0.5%), nausea (0.6%), and vomiting (0.5%).

Approximately 6% of 1,320 patients who received zolpidem at all doses (5 to 50 mg) in similar foreign trials discontinued treatment because of an adverse event. Events most commonly associated with discontinuation from these trials were daytime drowsiness (1.6%), amnesia (0.6%), dizziness (0.6%), headache (0.6%), and nausea (0.6%).

Incidence in controlled clinical trials

Most commonly observed adverse events in controlled trials: During short-term treatment (up to 10 nights) with Ambien at doses up to 10 mg, the most commonly observed adverse events associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were drowsiness (reported by 2% of zolpidem patients), dizziness (1%), and diarrhea (1%). During longer-term treatment (28 to 35 nights) with zolpidem at doses up to 10 mg, the most commonly observed adverse events associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were dizziness (5%) and drugged feelings (3%).

Incidence of Treatment-Emergent Adverse Experiences in Short-term Placebo-Controlled Clinical Trials
(Percentage of patients reporting)

Body System/ Adverse Event*	Zolpidem (≤ 10 mg) (N=685)	Placebo (N=473)
Central and Peripheral Nervous System		
Headache	7	6
Drowsiness	2	–
Dizziness	1	–
Gastrointestinal System		
Nausea	2	3
Diarrhea	1	–
Musculoskeletal System		
Myalgia	1	2

*Events reported by at least 1% of Ambien patients are included.

Incidence of Treatment-Emergent Adverse Experiences in Long-term Placebo-Controlled Clinical Trials
(Percentage of patients reporting)

Body System/ Adverse Event*	Zolpidem (≤ 10 mg) (N=152)	Placebo (N=161)
Autonomic Nervous System		
Dry mouth	3	1
Body as a Whole		
Allergy	4	1
Back pain	3	2
Influenza-like symptoms	2	–
Chest pain	1	–
Fatigue	1	2
Cardiovascular System		
Palpitation	2	–
Central and Peripheral Nervous System		
Headache	19	22
Drowsiness	8	5
Dizziness	5	1
Lethargy	3	1
Drugged feeling	3	–
Lightheadedness	2	1
Depression	2	1
Abnormal dreams	1	–
Amnesia	1	–
Anxiety	1	1
Nervousness	1	3
Sleep disorder	1	–
Gastrointestinal System		
Nausea	6	6
Dyspepsia	5	6
Diarrhea	3	2
Abdominal pain	2	2
Constipation	2	1
Anorexia	1	1
Vomiting	1	1
Immunologic System		
Infection	1	1
Musculoskeletal System		
Myalgia	7	7
Arthralgia	4	4

Incidence of Treatment-Emergent Adverse Experiences in Long-term Placebo-Controlled Clinical Trials (Cont'd)
(Percentage of patients reporting)

Body System/ Adverse Event*	Zolpidem (≤ 10 mg) (N=152)	Placebo (N=161)
Respiratory System		
Upper respiratory infection	5	6
Sinusitis	4	2
Pharyngitis	3	1
Rhinitis	1	3
Skin and Appendages		
Rash	2	1
Urogenital System		
Urinary tract infection	2	2

*Events reported by at least 1% of patients treated with Ambien.

There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse events associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.

Adverse events are further classified and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.

Frequent: abdominal pain, amnesia, ataxia, confusion, depression, diarrhea, dipiopia, dizziness, dreaming abnormal, drowsiness, drugged feeling, dry mouth, dyspepsia, euphoria, fatigue, headache, insomnia, lethargy, lightheadedness, myalgia, nausea, upper respiratory infection, vertigo, vision abnormal, vomiting.

Infrequent: agitation, allergy, anorexia, anxiety, arthralgia, arthritis, asthenia, back pain, bronchitis, cerebrovascular disorder, chest pain, constipation, coughing, cystitis, decreased cognition, detached, difficulty concentrating, dysarthria, dysphagia, dyspnea, edema, emotional lability, eye irritation, falling, fever, flatulence, gastroenteritis, hallucination, hiccup, hyperglycemia, hypertension, hypoaesthesia, infection, influenza-like symptoms, malaise, menstrual disorder, migraine, nervousness, pallor, palpitation, paresthesia, pharyngitis, postural hypotension, pruritus, rash, rhinitis, scleritis, SGPT increased, sinusitis, sleep disorder, sleeping (after daytime dosing), stupor, sweating increased, tachycardia, taste perversion, tinnitus, tooth disorder, trauma, tremor, urinary incontinence, urinary tract infection, vaginitis.

Rare: abdominal body sensation, abscess, acne, acute renal failure, aggressive reaction, allergic reaction, allergy aggravated, anaphylactic shock, anemia, appetite increased, arrhythmia, arteritis, arthrosis, bilirubinemia, breast fibroadenosis, breast neoplasm, breast pain female, bronchospasm, bullous eruption, BUN increased, circulatory failure, corneal ulceration, delusion, dementia, depersonalization, dermatitis, dysphasia, dysuria, edema periorbital, enteritis, epistaxis, eructation, esophagospasm, ESR increased, extrasystoles, eye pain, face edema, feeling strange, flushing, furunculosis, gastritis, glaucoma, gout, hemorrhoids, hepatic function abnormal, herpes simplex, herpes zoster, hot flashes, hypercholesteremia, hyperhemoglobinemia, hyperlipidemia, hypertension aggravated, hypotension, hypotonia, hypoxia, hysteria, illusion, impotence, injection site inflammation, intestinal obstruction, intoxicated feeling, lacrimation abnormal, laryngitis, leg cramps, leukopenia, libido decreased, lymphadenopathy, macrocytic anemia, manic reaction, micturition frequency, muscle weakness, myocardial infarction, neuralgia, neuritis, neuropathy, neurosis, otitis externa, otitis media, pain, panic attack, paresis, personality disorder, phlebitis, photopsia, photosensitivity reaction, pneumonia, polyuria, pulmonary edema, pulmonary embolism, purpura, pyelonephritis, rectal hemorrhage, renal pain, restless legs, rigors, saliva altered, sciatica, SGOT increased, somnambulism, suicide attempt, syncope, tendinitis, tenesmus, tetany, thinking abnormal, thirst, tolerance increased, tooth caries, urinary retention, urticaria, varicose veins, ventricular tachycardia, weight decrease, yawning.

DRUG ABUSE AND DEPENDENCE

Controlled substance: Schedule IV.

Abuse and dependence: Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg was difficult to distinguish from placebo.

Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. The U.S. clinical trial experience from zolpidem does not reveal any clear evidence for withdrawal syndrome. Nevertheless, the following adverse events included in DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported at an incidence of ≤1% during U.S. clinical trials following placebo substitution occurring within 48 hours following last zolpidem treatment: fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort.

Individuals with a history of addiction to, or abuse of, drugs or alcohol are at risk of habituation and dependence; they should be under careful surveillance when receiving any hypnotic.

OVERDOSAGE

Signs and symptoms: In European postmarketing reports of overdose with zolpidem alone, impairment of consciousness has ranged from somnolence to light coma, with one case each of cardiovascular and respiratory compromise. Individuals have fully recovered from zolpidem tartrate overdoses up to 400 mg (40 times the maximum recommended dose). Overdose cases involving multiple CNS-depressant agents, including zolpidem, have resulted in more severe symptomatology, including fatal outcomes.

Recommended treatment: General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Flumazenil may be useful. Respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Sedating drugs should be withheld following zolpidem overdosage. Zolpidem is not dialyzable.

The possibility of multiple drug ingestion should be considered.

Caution: Federal law prohibits dispensing without prescription.

4/11/94

Manufactured and distributed by
G.D. Searle & Co.
Chicago, IL 60680
by agreement with
Lorex Pharmaceuticals
Skokie, IL

Address medical inquiries to:
G.D. Searle & Co.
Medical & Scientific Information Department
4901 Searle Parkway
Skokie, IL 60077

SEARLE *Box 5110 Chicago, IL 60680-5110*

Aug 1994
P94AB9907T

Your Best Lines of Defense Against Disease are the Facts



Morbidity & Mortality Weekly Report gives you the facts.

Every week the experts at the Centers for Disease Control and Prevention report the facts on disease trends, epidemiological reports and health recommendations. Better than mere summaries, these reports (complete with charts, maps and tables) *pinpoint disease trends by region.* You'll know exactly what's happening in your part of the world as it occurs. No other source can offer you this fast breaking information — *as it happens.* Subscribe today, and get the facts.

☐ **YES!** I want the facts on the latest medical trends as reported by the CDC. Please enter my one-year subscription (52 weekly issues) to ***MMWR*** for $59.00.* **SPECIAL BONUS:** Subscribe today and receive **FREE** ***Recommendations and Reports*** and ***Surveillance Summaries*** as released by the CDC.

☐ My payment for _____ is enclosed.*
☐ Please charge to my credit card:
☐ MasterCard ☐ Visa ☐ AmEx
#
Expire Date
Signature
Credit Card Orders: Call 1 (800) 843-6356

RISK-FREE GUARANTEE: You may cancel your subscription at any time and receive a full refund on all unmailed issues.

Name
Address
City State Zip
Medical Specialty

Please allow 4–6 weeks for delivery of first issue. Rates subject to change without notice.
*Make checks payable to ***MMWR.***

Massachusetts Medical Society
P.O. Box 9120, Waltham, MA 02254-9120

SDWH2



HIV Infection: A Primary Care Approach

An essential guide for all clinicians.

Now in its Second Edition, ***HIV Infection*** gives you practical guidance on HIV patient care. It will help you to:

- Identify patients at risk
- Take an HIV-related history
- Establish a primary care relationship
- Prepare for patients' disability and death

The **Second Edition** has been expanded to give you up-to-date, reliable information that you can use in your practice. Substantial revisions in these areas:

- New and updated treatment tables
- Antiretroviral therapies
- Immunizations
- Opportunistic infections
- Prognostic markers
- Approach to symptoms

Completely revised and updated!

Send for your copy today, or ORDER TOLL FREE 1-800-843-6356.

About the Authors

Bruce Soloway, MD, is Medical Director of the Bronx-Lebanon Family Practice Center and is a faculty member at the Institute for Urban Family Health in New York City.

Frederick M. Hecht, MD, is Assistant Professor of medicine at the University of California in San Francisco and is an Attending Physician in the Division of General Internal Medicine at San Francisco General Hospital.

Adapted from articles published in *AIDS Clinical Care* newsletter.

©1994, 64 pages, 8.5″×11″, illustrated, paperback
ISBN: 0-910133-39-5

❑ **YES!** Please send me ____ copies of ***HIV Infection: A Primary Care Approach, Second Edition,*** at US $9.95.
*For multiple copy orders: (2-19 copies) US $8.95; (20+ copies) US $7.95. Prices include postage and handling.**

Check enclosed for a total of $_____.
Please charge my ❑ VISA ❑ MasterCard ❑ AmEx
CARD # _____ EXP. DATE _____
SIGNATURE _____
NAME _____
ADDRESS _____
_____
CITY _____ STATE ____ ZIP CODE _____

Call TOLL FREE: 1-800-843-6356
or order by FAX: (617) 893-0413.

*All orders must be prepaid. Make checks payable to ***HIV Infection.*** Massachusetts residents must add 5% sales tax.
Please allow 4-6 weeks for delivery.

Send to: *HIV Infection,* P.O. Box 9130, Waltham, MA 02254-9130

The Publishing Division of the Massachusetts Medical Society

SDQH3

If you're seeking nothing less than the perfect practice in the ideal location...

We have a number of opportunities.

If you're like most physicians, you've been relying on journals like *The New England Journal of Medicine* for years to locate the best practice opportunities in the country. Now, learn about career openings by phone, too -- 24 hours a day, 7 days a week. Introducing the National TeleAccess Network, a revolutionary new service that is:

Free. There are no charges of any kind for physician callers.
Confidential. You won't be contacted by employers unless you request.

Targeted. Specify your career interest, geographic preferences and more.
Fast. Request and receive details by fax or mail on openings that interest you.
Comprehensive. Browse through a variety of opportunities from all across the country.

Put your career search in high gear. Turn to *The New England Journal of Medicine* AND the National TeleAccess Network. It's an unbeatable combination. And it's your call.

1-800-682-1191

National TeleAccess Network
NTN
The Database of Physician Opportunities

In cooperation with
The New England Journal
of Medicine. 617-893-3800

The Journal of the American Board of Family Practice

Classified Advertising Section

The classified rate is $1.40 per word (minimum charge of $75.00 per ad insertion) and $90.00 per column inch for classified display ads. Please call 1-800-635-6991 and ask for classified advertising for rate information on various classified display ad sizes. Prepayment in full is required with all classified advertising. We accept American Express, VISA, or MasterCard. Confidential reply boxes are an additional $10.00 per insertion. Responses are sent directly every Tuesday and Thursday, and the box will remain open for three months.

Note: Our classified advertisements are all set in the same typeface and format. All ads are listed by geographic territory.

Classified advertisements placed with JABFP are restricted to physician recruitment, faculty positions, CME courses/seminars, and practices for sale. All ads must relate to the medical field and are subject to approval.

Please refer to the schedule below for closing dates. All advertisements for employment must be nondiscriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted.

Classified advertising orders, correspondence, and payments should be directed to:

Classified Advertising
JABFP
1440 Main Street
Waltham, MA 02154

or call 1-800-635-6991
(617-893-3800 in MA)
FAX: 617-895-1045

Classified Advertising Deadlines

Issue Date	Closing Date
January-February	December 1
March-April	February 1
May-June	April 1

Northeast

FAMILY PRACTICE — CENTRAL NEW HAMPSHIRE — New London Hospital seeks a board certified/eligible Family Practitioner for growing, exciting group practice opportunity. Excellent salary, liberal vacation and CME benefit package. The hospital is in excellent financial position for the future. We are close to major medical teaching facilities yet still retain the New England small town charm. The New London/Lake Sunapee area of New Hampshire is rated one of the most attractive in New England. We enjoy the four seasons with skiing, boating, hiking and other outdoor activities. Please forward resume to: Ray Bonito, Vice President for Ambulatory and Professional Services, New London Hospital, 270 County Road, New London, NH 03257.

MAINE — Superb FP opportunity now available on Maine's southern seacoast. Global practice includes lab, x-ray, physical therapy, endoscopy and more. Excellent salary plus bonus and professional expenses. Comprehensive benefits. Two years to partnership. One-in-four call coverage. OB would be essential. Enjoy boating, sailing, skiing, golf, culture, shopping in this mid-sized coastal community. Just 25 miles to Portland and 90 minutes to Boston. For further details send CV in confidence to: Jonathan Shill, MD, The Medical Group, 3 Meadows Lane, Kennebunk, ME 04043 or call: 207-985-7174.

NEW JERSEY'S DELIGHTFUL BERGEN COUNTY — Exceptional opportunity for BC/BE Family Practitioner to join five-physician group in a charming suburban community only thirty minutes from New York City. Complete lab, x-ray and surgical facilities. Guaranteed income leading to potential partnership. Contact: John C. Rogers, Medical Management Associates, 102 South Maple Avenue, Ridgewood, NJ 07450. Call: 201-444-2144.

LEADERSHIP/SUPERVISORY OPPORTUNITY — Coastal Southern Maine, for experienced BC Family Practitioner to work in one of five multispecialty health center locations. Join largest primary care group in state. Enjoy nearby ocean, mountains and lakes, plus cultural and college-town amenities. Progressive environment with emphasis on managed care offers teamwork, reasonable working hours, 1:4-5 call. Financial security of competitive salary, incentive bonus plan, excellent benefits package. Satisfy family needs for excellent education and safety of small city living with easy commute to Portland. Great skiing, sailing, hiking and more. Wonderful place to raise your children. Please call or send CV to: Renee Campbell, Provider Recruitment, Martin's Point Health Care Centers, PO Box 9746, Portland, ME 04104-5040, 800-348-9804.

COASTAL SOUTHERN MAINE & NEW HAMPSHIRE — Largest primary care group in Maine expanding — seeks additional BC/BE family practitioners in several of five multispecialty health center locations in Maine and NH. Enjoy nearby ocean, mountains and lakes, plus cultural and academic amenities. Progressive environment with emphasis on managed care offers teamwork, reasonable working hours, 1:4-5 call. Financial security of competitive salary, incentive bonus plan, excellent benefits package. Satisfy family needs for excellent education and safety of small city living with easy commute to Portland and Boston. Great skiing, sailing, hiking and more. Wonderful place to raise your children. Please call or send CV to: Renee Campbell, Provider Recruitment, Martin's Point Health Care Centers, PO Box 9746, Portland, ME 04104-5040, 800-348-9804.

WESTCHESTER COUNTY, NEW YORK — BE/BC FP for busy family medicine practice. Lucrative compensation package. Send CV to: Jules Ehrenberg, E.J. Michaels, 1865 Palmer Avenue, Larchmont, NY 10538. Call: 914-833-1700 or toll-free outside the New York metropolitan area at: 800-333-2999. Fax: 914-833-1711.

SOUTHWESTERN CONNECTICUT — FAMILY PRACTICE — HOSPITAL GUARANTEE — Lucrative private practice offer. Contact: Mimi Kozma, VP, E.J. Michaels, Ltd., 1865 Palmer Avenue, Suite 101, Larchmont, NY 10538. Or call: 914-833-1700 or 800-333-2999 outside the NY metropolitan area. Or fax your CV to: 914-833-1711.

WESTERN NEW YORK/WESTERN PENNSYLVANIA AND SCRANTON/WILKES-BARRE, PENNSYLVANIA — BE/BC Family Practitioners sought for hospital-based and private practice positions. Outstanding compensation. Send CV: Shelley Carhill, E.J. Michaels, Ltd., 1865 Palmer Avenue, Suite 101, Larchmont, NY 10538. Phone: 914-833-1700 or 800-333-2999 (outside NY metropolitan area). Fax: 914-833-1711.

SYRACUSE NY/FINGER LAKES AREA — BE/BC FP to join seven-physician primary care group; no weekend/night call; compensation to $175,000. Send CV to: Jules S. Ehrenberg, VP, E.J. Michaels, Ltd., 1865 Palmer Avenue, Suite 101, Larchmont, NY 10538. Phone: 914-833-1700 or 800-333-2999 (outside NY metropolitan area). Fax: 914-833-1711.

INTERNIST/FAMILY PRACTITIONER — BC/BE. Interest in purchasing existing practice in Northeastern Pennsylvania. Excellent potential. Financial assistance may be available for the practice as well as relocation. Reply Box 10197, JABFP.

NEW YORK — HUDSON RIVER COMMUNITY, WESTCHESTER COUNTY — Ten minutes to USMA at West Point, fifty minutes to NYC. Established solo FP, age 42, seeks one or two FP trained BE/BC FP's to share unique full range booming meticulous office/hospital practice. Includes police and industrial medicine, endoscopy and minor surgery in quaint newly renovated office. OB optional. Two miles from expanding 125-bed community hospital with full privileges including OR and ICU. Teaching opportunities through New York Medical College precepting medical students. Salary guarantee, incentives, partnership and most importantly, a fun practice to join. This is a dream opportunity. Send CV to: John A. McGurty, Jr., MD, 211 South Division Street, Peekskill, NY 10566. 914-736-0400.

FAMILY PRACTITIONER — Is seeking an Associate/Partner for opportunity in north central Pennsylvania. Salary guarantee of $100,000 with potential of $200,000 in the second year. Physician can perform a variety of endoscopic procedures, pulmonary function testing, EKG's, etc. Located one hour from prime ski resorts and 2.5 hours from Pittsburgh. Strong supportive community, low cost of living, good schools, low crime rate, ideal location for raising a family. For more information contact: Durham Medical Search, Inc., 6300 Transit Road, PO Box 478, Depew, NY 14043. Or call toll-free: 800-633-7724 (USA), 800-367-2356 (NYS), 716-681-7408 (FAX).

FAMILY PRACTICE — Pennsylvania multispecialty group offering aggressive salary and benefit package including car allowance, 24 days vacation/CME, matching 401k plan, CME allowance, paid malpractice, health/life/disability. Professionally managed, well-established group of board certified physicians with a strong emphasis on patient care and physicians' quality of life. Metropolitan area with access to the seashore and mountains, with a low cost of living you'll appreciate. For more information call: Tom Bell at 800-238-7150 or fax your CV with a note to: 215-975-0574.

TEMPLE UNIVERSITY SCHOOL OF MEDICINE — CHAIRPERSON OF FAMILY PRACTICE AND COMMUNITY HEALTH — Temple University School of Medicine is seeking a Chairperson for its Department of Family Practice and Community Health. Applicants for this full-time position must have board certification; academic experience with qualifications for appointment as Full Professor; demonstrated excellence in education and patient care; outstanding interpersonal and leadership skills; the ability to develop strong clinical/academic programs and to maintain effective ongoing associations with the institutions and practices essential to our required clinical clerkship; the knowledge and skills to develop and sustain a competitive residency program. Applicants should send their resumes and bibliographies to: Ms. Betty E. Berdel, Secretary to the Family Practice Search Committee, Office of the Dean, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140. Temple is an Affirmative Action/Equal Opportunity Employer and strongly encourages applications from women and minorities.

Southeast

MANAGED CARE BLUES? — Try primary care without the headaches! Internists or Family Practitioners (BC) to join practices in our growing retirement communities in the suburbs of Baltimore. Practice financially supported by communities to allow for high quality care in a stable "Health Care Reform Proof" environment. Diverse positions with rewarding clinical practice, research opportunities, administration and teaching. Faculty appointment at Johns Hopkins University commensurate with qualifications. Geriatric experience preferred but not required. Communities have full range of clinical and social services to support a multidisciplinary approach to the practice of medicine. Very competitive salary and generous benefit package including health, life, disability and malpractice insurance, flexible benefit program, five weeks vacation/personal and one week CME. Send CV to: Gary Applebaum, MD, VP, Medical Services, Senior Campus Living, 711 Maiden Choice Lane, Baltimore, MD 21228, or call: 410-247-5602.

TYLER & COMPANY — Is seeking an MD for the position of Executive Vice President, Clinical Services for SunHealth Alliance, whose corporate offices are located in the growing progressive southeastern city of Charlotte, North Carolina. Please contact: Robin Singleton at 800-883-8803 or fax CV to 404-396-6693. All inquiries are confidential.

RESIDENCY DIRECTOR, DEPARTMENT OF FAMILY MEDICINE — MEDICAL UNIVERSITY OF SOUTH CAROLINA, CHARLESTON, SOUTH CAROLINA — This well-established university-based 36 residency program is looking for a Residency Director. The successful applicant will be a leader with an evident commitment to education, service and scholarly activity. The program excels in prevention, the doctor-patient relationship and electronic data systems. Charleston, South Carolina is a beautiful coastal city with a charming historic downtown area. The Medical University of South Carolina is an Equal Opportunity/Affirmative Action Employer. Submit a letter of interest to: Clive D. Brock, MD, Professor and Associate Chairman of Education, Department of Family Medicine, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425.

GREATER CINCINNATI "AMERICA'S MOST LIVABLE CITY" — No call/full-time scheduled hours for a board certified Family Practice or Internal Medicine Physician. St. Luke Hospital West is a 177-bed facility located twelve miles from downtown Cincinnati in Florence, Kentucky. We are seeking a staff physician whose duties will include responding to emergencies, and performing employee health and occupational medicine services. Compensation: $117+k plus comprehensive benefit package. Please respond in confidence to: Brenda Ziegler, Physician Recruiter 800-345-7151, extension 3361 or fax: 606-572-3369.

EXCEPTIONAL OPPORTUNITY FOR A FAMILY PRACTITIONER — Located in Southwest Kentucky. New (grand opening 8/93) 107-bed medical facility offers state-of-the-art equipment and patient care. Doctor professional building is attached to the hospital which also offers the newest in business systems. Primary service area of 135,000 with one in eight call coverage or outpatient clinic practice setting. Very competitive financial package. Family oriented community with schools nationally recognized for their academic excellence. Cultural amenities include community theater, nearby university and area symphony. Just minutes from two of the largest man-made lakes in the world. For more information, send your CV or call: Richard Whidby, Jackson & Coker, 115 Perimeter Center Place, Suite 380 (14023), Atlanta, GA 30346; Telephone: 800-272-2707, extension 14023.

PHYSICIAN WANTED — FAMILY PRACTICE OR INTERNAL MEDICINE — As associate in large, mostly HMO, solo practice. Located in Miami Shores, Florida. Must be board certified or board eligible in FP or IM and willing to be credentialed by numerous HMO's. Send CV to: Ira S. Jacobson, MD, 1190 NW 95th Street, Suite 401, Miami, FL 33150. Attn: Leslie. 305-835-2511.

Midwest

TOLEDO, OHIO — Family Practice, BC/BE FP for group practice. One-in-three coverage. Outstanding salary and benefits. Send CV to: Jules Ehrenberg, E.J. Michaels, 1865 Palmer Avenue, Larchmont, NY 10538. Call: 914-833-1700. Outside the NY metropolitan area: 800-333-2999. Fax: 914-833-1711.

DANVILLE/CHAMPAIGN-URBANA AREA, ILLINOIS — BE/BC FP sought for three-physician practice. One-in-three coverage; high income potential. Send CV: E.J. Michaels, Ltd., 1865 Palmer Avenue, Suite 101, Larchmont, NY 10538. Phone: 914-833-1700, 800-333-2999 (outside NY metropolitan area). Fax: 914-833-1711.

FAMILY PRACTICE — Group of three is looking for a fourth. Salary of $130,000 with $20,000 sign-on bonus and full benefits. Great family community with arts, theatre and symphony forty minutes away in Northwestern Illinois. For more information call: Durham Medical Search, Inc., 6300 Transit Road, PO Box 478, Depew, NY 14043. 800-633-7724 (USA), 800-367-2356 (NYS), 716-681-7408 (FAX).

110-PHYSICIAN MIDWEST MULTISPECIALTY — BC/BE candidates: dermatology, family medicine, pulmonology. Fourteen-county area healthcare center, draw over 320,000. Guaranteed salary first two years. Thriving family community. Purdue University offers academics, cultural events, Big 10 sports. Contact: Physician Recruitment, Arnett Clinic, PO Box 5545, Lafayette, IN 47904. 800-899-8448.

FAMILY PRACTICE PHYSICIAN WANTED — BC/BE for community health center in rural practice setting in SE Michigan. Located within 35 miles of Detroit, Ann Arbor, and Toledo. Competitive salary and incentives plus an excellent benefits package. Contact: Fay Thiel/Pat Cavanagh, Michigan Primary Care Association, 1200 East Michigan Avenue, Suite C, East Lansing, MI 48823. 800-752-7268 or 517-336-5900.

NORTHEASTERN WISCONSIN — Six-person FP group is recruiting BE/BC Physician. Busy practice with full range of clinical services, including OB. Comfortable community with an excellent lifestyle. Located between Green Bay and Milwaukee. Low crime. Excellent schools. Several colleges and universities nearby. Competitive salary, productivity bonus, and fringe benefits. Send CV to: Reply Box 10380, JABFP.

MICHIGAN — War Memorial Hospital in Sault Ste. Marie, Michigan is assisting a well-respected, board certified FP in our community in the recruitment of a board prepared/certified Family Physician to be the core of a single specialty group. OB and procedures are optional. Excellent compensation and benefits available. Located in the beautiful Eastern Upper Peninsula of Michigan, Sault Ste. Marie is a mecca of both winter and summer outdoor recreation and offers a superior quality of life. For more information contact: Elisa Abner-Taschwer at 800-635-4608 or forward your CV to: War Memorial Hospital, 500 Osborn Boulevard, Sault Ste. Marie, MI 49783.

IOWA — A FAMILY PHYSICIAN'S FAMILY HAVEN — Bring your family to a safe wholesome area rich with leisure, cultural and educational opportunities. We are in need of BE/BC Family Physicians to join our growing PHO of primary care physicians. Highly competitive salary and compensation package. Practice patient-oriented medicine in a group concerned with your quality of life. Send CV to: Theresa Alberts, Recruiting Specialist, 855 A Avenue NE, Suite 100, Cedar Rapids, IA 52402. Telephone: 319-366-3400.

ACADEMIC POSITION — Join the academic team in the Department of Family and Community Medicine at the University of Illinois College of Medicine at Rockford. This nationally recognized department has an opening for a physician in an innovative ambulatory primary care setting where faculty supervise medical students in delivering health care. As students spend one day a week for 2.5 years following up to 100 families, this is the perfect opportunity to combine genuine clinical practice with effective one-on-one teaching in an academic environment. Candidates must be board certified/board eligible. A willingness to provide obstetrical care is desirable. Rank commensurate with qualifications. Scholarly time is available and beginning faculty can qualify for a new two year Faculty Development Fellowship. Innovative programs of teaching and research in rural medical education, patient-centered clinical method, international medical education and in community-based medical education are in progress. The environment for family medicine at the College of Medicine at Rockford is outstanding. Come join with us in our vision! For further discussion please contact: Ron McCord, MD, 1601 Parkview Avenue, Rockford, IL 61107-1897. 815-395-5810. The University of Illinois is an Equal Opportunity/Affirmative Action Employer.

JOIN A YOUNG, "TRUE FAMILY" PRACTITIONER — Whose closed practice mandates that he add a partner. Rent free, cost sharing arrangement for first two years leading into a no buy-in partnership. Hire your RN, the partner provides the ancillary staff. Modern office in a doctor's park. One-in-three call. Culture provided by Southern Illinois University. Phone: Andrew H. Marcec or Sue Ridgway at 800-333-1929 at Memorial Hospital, Carbondale, IL 62901.

Southwest

OKLAHOMA — Experience the hospitality of the southwest in Oklahoma. We are interested in the addition of BC/BE family physicians to join our growing multispecialty group practice. Salary guarantee, incentive bonus and generous benefits are offered. Contact: Debbie Jones, *Oklahoma City Clinic, 701 NE 10th, Oklahoma City, OK 73104.* 800-522-0224, ext. 2591.

BROOKE ARMY MEDICAL CENTER, FORT SAM HOUSTON, TEXAS — Seeking two Family Practice MD's for new Family Care Clinic. Offers competitive benefit package for board certified FP's. Contact: Family Care Clinic, Building 1279, Garden Avenue, Fort Sam Houston, TX 78234. 210-916-7881 (Mrs. Yon) or 210-916-6288 (Maj. Evans) or fax CV to: 210-916-6595 Attn: Maj. Evans.

EXCELLENT OPPORTUNITIES AVAILABLE IMMEDIATELY — For BC/BE Family Practitioners to staff family practice clinics in a sunny southeast Texas community close to a large metro city and which offers an excellent quality of life and good schools. Extremely competitive first year net income guarantee with the potential for succeeding years exceptional. With these opportunities the hassle of managing an office is gone. Interview, relocation and marketing expense underwritten. Interested applicants please forward CV to: Pat Adams, AMI Park Place Medical Center, PO Box 1648, Port Arthur, TX 77641 or fax to: 409-983-6152.

SEEKING BOARD CERTIFIED FP OR INTERNIST — To serve as Medical Director of 40+ member, non-profit primary care group. Administrative duties will include recruitment and development of outstanding practitioners, coordination of resident education activities, compensation issues, and generally building on the momentum which the group has already achieved. Must be willing to devote a substantial proportion of time to patient care and must be capable of establishing a high standard by example. Compensation negotiable. Administrative experience or training preferred. Please send CV to: Patrick Williamson, MD, Solomon Anthony Clinic, 2833 Babcock, Suite 200, San Antonio, TX 78229 or fax: 210-616-7343.

ALBUQUERQUE, NEW MEXICO — BE/BC Family Practice Physicians. Numerous opportunities with the region's leading healthcare system. Competitive salary, personalized benefits and potential for incentive compensation. Send CV: Kay Kernaghan, Physician Coordinator, Presbyterian Healthcare Services, PO Box 26666, Albuquerque, NM 87125. Telephone: 800-545-4030, x6330. Fax: 505-260-6393.

PRACTICE/TEACHING POSITION IN SOUTHERN NEW MEXICO — Memorial Medical Center in Las Cruces, NM is seeking family physician faculty to develop a new family practice residency program in collaboration with the University of New Mexico. Position involves direct patient care (preferably with obstetrics), teaching and involvement in primary care research. Board certification required, fellowship training or prior teaching experience preferred. Competitive salary and fringe benefits, university faculty appointment and excellent quality of life. For information contact: Michael Stehney, MD at 505-521-3045 during the day or 505-521-3891 after 6pm MST.

Colorado

FAMILY PRACTICE PHYSICIAN BC/BE — Salud, a progressive family practice group with ten offices, seeks skilled physician for brand new Fort Morgan, Colorado location. Practice includes OB and offers paid malpractice, CME and easy call schedule. Close to great skiing! Call: 800-388-4325.

Pacific

RESIDENCY PROGRAM ASSOCIATE DIRECTOR — Fully accredited glorious Northern California Residency Program is seeking board certified Family Physician. Physician Educator or fellowship training preferred. Responsibilities include program director support, resident documentation, and curriculum evaluation; 30% clinical work and 30% teaching are required. OB strongly encouraged. Flexibility, enthusiasm, innovation are key characteristics desired in the ideal candidate. UC Davis affiliated residency program. Contact: Rich McNabb, MD, MPH, Residency Director, Merrithew Memorial Hospital, 2500 Alhambra Avenue, Martinez, CA 94553, 510-370-5117. Equal Opportunity Employer.

OREGON — PLAYGROUND OF THE PACIFIC NORTHWEST! — Ocean beaches, old growth forests, semi-arid deserts, raging rivers, snow-capped mountains, hot springs, fossil beds and vineyards. Oregon Health Sciences University represents a variety of practice opportunities for Family Practitioners and General Internists in communities of 300-30,000. Call the OHSU switchboard, 800-328-2422, ask for Scott in Office of Rural Health.

PRACTICE AT THE GATEWAY TO MOUNT HOOD! — Join three Family Physicians in an opportunity that uniquely blends the advantages of practicing and living in a smaller community with the amenities of downtown Portland only 45 minutes away. BC/BE a must. NO obstetrics. Excellent income potential. Send CV to: Cynthia Lacro, Legacy Health System, 1919 NW Lovejoy, Portland, OR 97209. 503-225-8769.

Multiple Locations

OUR CLIENTS ARE SEEKING BE/BC PRIMARY CARE PHYSICIANS — OB/GYN, Child/Adolescent Psychiatrist, General Psychiatrist. Great group practice opportunities in MD, NJ, NY, CT, VA, TX, TN. Excellent salary, benefits and bonus. No recruitment fee. 95's accepted. Fax CV to: The Park Group 610-695-0979 or call: 800-381-2020.

PHYSICIANS

Natividad Medical Center is presently seeking **Family Practitioners** to join our Family Practice Residency Program and Affiliated Community Clinics. Position highlights include:

- ❒ *Residency affiliated with the University of California, San Francisco*
- ❒ *HPSA designation offering the potential for loan repayment*
- ❒ *Modern, affordable health care campus on present site to be completed by 1997*
- ❒ *Located 17 miles inland from the beautiful Monterey Bay, Salinas offers a community of 110,000 and moderate year-round weather.*

You must be Board Certified / Board Eligible as a Family Practitioner. Obstetrics preferred for Residency Faculty position, optional for community clinics.

If this opportunity sounds like what you are looking for and you are ready to join an energetic team, please request more information by contacting:

Richard Brunader, M.D.
Director, Family Practice Residency Program
Natividad Medical Center
P.O. Box 81611, Salinas, CA 93912
(408) 755-4201
AA/EOE

NATIVIDAD MEDICAL CENTER.

FRIENDLY PEOPLE, FAMILY MEDICINE.

FOR A CHANGE OF PACE

Serve your country, enhance your skills and practice your speciality in the greatest Navy in the world. The Naval Reserve has it all, part-time. Call: 1-800-USA-USNR.

NAVAL RESERVE
You and the Naval Reserve. Full Speed Ahead.

Response.
Response.
Response.

JABFP classified ads deliver.

How does an extra



$10,000 sound?



For a compact disc or audio tape on how you can receive a stipend of up to $10,000 a year as a civilian surgical resident through the Army Reserve's Specialized Training Assistance Program, call 1-800-USA-ARMY, ext. 428.

ARMY RESERVE MEDICINE. BE ALL YOU CAN BE.